% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Rehn:1032435,
      author       = {Rehn, Fabian and Kraemer-Schulien, Victoria and Bujnicki,
                      Tuyen and Bannach, Oliver and Tschoepe, Diethelm and
                      Stratmann, Bernd and Willbold, Dieter},
      title        = {{IAPP} - oligomerisation levels in plasma of people with
                      type 2 diabetes},
      journal      = {Scientific reports},
      volume       = {14},
      number       = {1},
      issn         = {2045-2322},
      address      = {[London]},
      publisher    = {Macmillan Publishers Limited, part of Springer Nature},
      reportid     = {FZJ-2024-06241},
      pages        = {19556},
      year         = {2024},
      abstract     = {Islet amyloid polypeptide (IAPP) is co-secreted with
                      insulin from pancreatic ß-cells. Its oligomerisation is
                      regarded as disease driving force in type 2 diabetes (T2D)
                      pathology. Up to now, IAPP oligomers have been detected in
                      affected tissues. IAPP oligomer concentrations in blood have
                      not been analysed so far. Using the IAPP
                      single-oligomer-sensitive and monomer-insensitive
                      surface-based fluorescence intensity distribution analysis
                      (sFIDA) technology, levels of IAPP oligomers in blood plasma
                      from healthy controls and people with T2D in different
                      disease stages where determined. Subsequently, the level of
                      IAPP oligomerisation was introduced as the ratio between the
                      IAPP oligomers determined with sFIDA and the total IAPP
                      concentration determined with ELISA. Highest oligomerisation
                      levels were detected in plasma of people with T2D without
                      late complication and without insulin therapy. Their levels
                      stand out significantly from the control group. Healthy
                      controls presented with the lowest oligomerisation levels in
                      plasma. In people with T2D without complications, IAPP
                      oligomerisation levels correlated with disease duration. The
                      results clearly demonstrate that IAPP oligomerisation in
                      insulin-naïve patients correlates with duration of T2D.
                      Although a correlation per se does not identify, which is
                      cause and what is consequence, this result supports the
                      hypothesis that IAPP aggregation is the driving factor of
                      T2D development and progression. The alternative and
                      conventional hypothesis explains development of T2D with
                      increasing insulin resistance causing exhaustion of
                      pancreatic ß-cells due to over-secretion of insulin, and
                      thus IAPP, too, resulting in subsequent IAPP aggregation and
                      fibril deposition in the pancreas. Further experiments and
                      comparative analyses with primary tissues are warranted.},
      cin          = {IBI-7},
      ddc          = {600},
      cid          = {I:(DE-Juel1)IBI-7-20200312},
      pnm          = {5241 - Molecular Information Processing in Cellular Systems
                      (POF4-524)},
      pid          = {G:(DE-HGF)POF4-5241},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {39174611},
      UT           = {WOS:001304514000052},
      doi          = {10.1038/s41598-024-70255-3},
      url          = {https://juser.fz-juelich.de/record/1032435},
}